Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris

D. Mimouni, M. Blank, L. Ashkenazi, Y. Milner, M. Frusic-Zlotkin, Grant James Anhalt, M. David, Yehuda Shoenfeld

Research output: Contribution to journalArticle

Abstract

Uncontrolled studies have found intravenous immunoglobulin (IVIG) to be effective in the treatment of pemphigus vulgaris (PV). The aim of this study was to evaluate the role of IVIG in preventing IgG autoantibodies binding to desmoglein-3 and blister formation using a controlled experimental design. The ability of IVIG to affect the binding of IgG affinity purified from two patients with PV to desmoglein-3 in comparison to IgG from one donor, was conducted by enzyme-linked immunosorbent assay (ELISA). The specificity was confirmed by competition assay. We assessed the effect of IVIG on the induction of experimental-PV in CD1 newborn mice by subcutaneous subjection of IgG affinity purified from two patients with PV. The treatment was conducted by subcutaneous administration of IVIG together with IgG from the pemphigus patients or appropriate control. The skin of the newborns was examined 24-48 h later for blisters, and samples of the affected areas were analysed by immunohistochemistry. IVIG as a whole molecule and its F(ab)2 portion inhibited the binding of anti-desmoglein-3 antibody to recombinant desmoglein-3 in a dose-dependent manner. The specificity was confirmed by competition assays. In-vivo, IVIG and its F(ab)2 portion prevented blister formation in the newborn mice. Cutaneous lesions were noted only in the groups of newborn mice who were injected with IgG fractions from the PV patients. Immunopathological evaluation revealed that IVIG prevented the formation of acanthylosis with IgG deposition in the intercellular spaces. These results point to the efficacy of IVIG in the prevention of blister formation in an experimental PV model.

Original languageEnglish (US)
Pages (from-to)426-432
Number of pages7
JournalClinical and Experimental Immunology
Volume142
Issue number3
DOIs
StatePublished - Dec 2005

Fingerprint

Pemphigus
Intravenous Immunoglobulins
Theoretical Models
Desmoglein 3
Immunoglobulin G
Blister
Skin
Extracellular Space
Autoantibodies
Research Design
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Tissue Donors
Newborn Infant
Antibodies

Keywords

  • Autoantibodies
  • Autoimmunity
  • Desmoglein
  • IVIG
  • Pemphigus

ASJC Scopus subject areas

  • Immunology

Cite this

Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris. / Mimouni, D.; Blank, M.; Ashkenazi, L.; Milner, Y.; Frusic-Zlotkin, M.; Anhalt, Grant James; David, M.; Shoenfeld, Yehuda.

In: Clinical and Experimental Immunology, Vol. 142, No. 3, 12.2005, p. 426-432.

Research output: Contribution to journalArticle

Mimouni, D, Blank, M, Ashkenazi, L, Milner, Y, Frusic-Zlotkin, M, Anhalt, GJ, David, M & Shoenfeld, Y 2005, 'Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris', Clinical and Experimental Immunology, vol. 142, no. 3, pp. 426-432. https://doi.org/10.1111/j.1365-2249.2005.02947.x
Mimouni, D. ; Blank, M. ; Ashkenazi, L. ; Milner, Y. ; Frusic-Zlotkin, M. ; Anhalt, Grant James ; David, M. ; Shoenfeld, Yehuda. / Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris. In: Clinical and Experimental Immunology. 2005 ; Vol. 142, No. 3. pp. 426-432.
@article{4e955cb1e9e64f09be0b284526fcca05,
title = "Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris",
abstract = "Uncontrolled studies have found intravenous immunoglobulin (IVIG) to be effective in the treatment of pemphigus vulgaris (PV). The aim of this study was to evaluate the role of IVIG in preventing IgG autoantibodies binding to desmoglein-3 and blister formation using a controlled experimental design. The ability of IVIG to affect the binding of IgG affinity purified from two patients with PV to desmoglein-3 in comparison to IgG from one donor, was conducted by enzyme-linked immunosorbent assay (ELISA). The specificity was confirmed by competition assay. We assessed the effect of IVIG on the induction of experimental-PV in CD1 newborn mice by subcutaneous subjection of IgG affinity purified from two patients with PV. The treatment was conducted by subcutaneous administration of IVIG together with IgG from the pemphigus patients or appropriate control. The skin of the newborns was examined 24-48 h later for blisters, and samples of the affected areas were analysed by immunohistochemistry. IVIG as a whole molecule and its F(ab)2 portion inhibited the binding of anti-desmoglein-3 antibody to recombinant desmoglein-3 in a dose-dependent manner. The specificity was confirmed by competition assays. In-vivo, IVIG and its F(ab)2 portion prevented blister formation in the newborn mice. Cutaneous lesions were noted only in the groups of newborn mice who were injected with IgG fractions from the PV patients. Immunopathological evaluation revealed that IVIG prevented the formation of acanthylosis with IgG deposition in the intercellular spaces. These results point to the efficacy of IVIG in the prevention of blister formation in an experimental PV model.",
keywords = "Autoantibodies, Autoimmunity, Desmoglein, IVIG, Pemphigus",
author = "D. Mimouni and M. Blank and L. Ashkenazi and Y. Milner and M. Frusic-Zlotkin and Anhalt, {Grant James} and M. David and Yehuda Shoenfeld",
year = "2005",
month = "12",
doi = "10.1111/j.1365-2249.2005.02947.x",
language = "English (US)",
volume = "142",
pages = "426--432",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris

AU - Mimouni, D.

AU - Blank, M.

AU - Ashkenazi, L.

AU - Milner, Y.

AU - Frusic-Zlotkin, M.

AU - Anhalt, Grant James

AU - David, M.

AU - Shoenfeld, Yehuda

PY - 2005/12

Y1 - 2005/12

N2 - Uncontrolled studies have found intravenous immunoglobulin (IVIG) to be effective in the treatment of pemphigus vulgaris (PV). The aim of this study was to evaluate the role of IVIG in preventing IgG autoantibodies binding to desmoglein-3 and blister formation using a controlled experimental design. The ability of IVIG to affect the binding of IgG affinity purified from two patients with PV to desmoglein-3 in comparison to IgG from one donor, was conducted by enzyme-linked immunosorbent assay (ELISA). The specificity was confirmed by competition assay. We assessed the effect of IVIG on the induction of experimental-PV in CD1 newborn mice by subcutaneous subjection of IgG affinity purified from two patients with PV. The treatment was conducted by subcutaneous administration of IVIG together with IgG from the pemphigus patients or appropriate control. The skin of the newborns was examined 24-48 h later for blisters, and samples of the affected areas were analysed by immunohistochemistry. IVIG as a whole molecule and its F(ab)2 portion inhibited the binding of anti-desmoglein-3 antibody to recombinant desmoglein-3 in a dose-dependent manner. The specificity was confirmed by competition assays. In-vivo, IVIG and its F(ab)2 portion prevented blister formation in the newborn mice. Cutaneous lesions were noted only in the groups of newborn mice who were injected with IgG fractions from the PV patients. Immunopathological evaluation revealed that IVIG prevented the formation of acanthylosis with IgG deposition in the intercellular spaces. These results point to the efficacy of IVIG in the prevention of blister formation in an experimental PV model.

AB - Uncontrolled studies have found intravenous immunoglobulin (IVIG) to be effective in the treatment of pemphigus vulgaris (PV). The aim of this study was to evaluate the role of IVIG in preventing IgG autoantibodies binding to desmoglein-3 and blister formation using a controlled experimental design. The ability of IVIG to affect the binding of IgG affinity purified from two patients with PV to desmoglein-3 in comparison to IgG from one donor, was conducted by enzyme-linked immunosorbent assay (ELISA). The specificity was confirmed by competition assay. We assessed the effect of IVIG on the induction of experimental-PV in CD1 newborn mice by subcutaneous subjection of IgG affinity purified from two patients with PV. The treatment was conducted by subcutaneous administration of IVIG together with IgG from the pemphigus patients or appropriate control. The skin of the newborns was examined 24-48 h later for blisters, and samples of the affected areas were analysed by immunohistochemistry. IVIG as a whole molecule and its F(ab)2 portion inhibited the binding of anti-desmoglein-3 antibody to recombinant desmoglein-3 in a dose-dependent manner. The specificity was confirmed by competition assays. In-vivo, IVIG and its F(ab)2 portion prevented blister formation in the newborn mice. Cutaneous lesions were noted only in the groups of newborn mice who were injected with IgG fractions from the PV patients. Immunopathological evaluation revealed that IVIG prevented the formation of acanthylosis with IgG deposition in the intercellular spaces. These results point to the efficacy of IVIG in the prevention of blister formation in an experimental PV model.

KW - Autoantibodies

KW - Autoimmunity

KW - Desmoglein

KW - IVIG

KW - Pemphigus

UR - http://www.scopus.com/inward/record.url?scp=28344432096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28344432096&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2249.2005.02947.x

DO - 10.1111/j.1365-2249.2005.02947.x

M3 - Article

C2 - 16297153

AN - SCOPUS:28344432096

VL - 142

SP - 426

EP - 432

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -